Discontinued ProductUnfortunately U 92016A (Cat. No. 2739) has been withdrawn from sale for commercial reasons.
Selective 5-HT1A receptor agonist that displays high intrinsic activity (Ki values are 0.4, 7.7 and 36 nM for 5-HT1A, 5-HT1D and D2 receptors respectively and > 1000 nM for 5-HT2, D1, α1 and α2 receptors). Produces hypothermia, hypotension and 5-HT behavioral syndrome following p.o. administration.
|Storage||Desiccate at RT|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Preparing Stock Solutions
The following data is based on the product molecular weight 331.88. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||3.01 mL||15.07 mL||30.13 mL|
|5 mM||0.6 mL||3.01 mL||6.03 mL|
|10 mM||0.3 mL||1.51 mL||3.01 mL|
|50 mM||0.06 mL||0.3 mL||0.6 mL|
References are publications that support the products' biological activity.
Romero et al (1993) Novel 2-substituted tetrahydro-3H-benz[e]indolamines: highly potent and selective agonists acting at the 5-HT1A receptor as possible anxiolytics and antidepressants. J.Med.Chem. 36 2066 PMID: 8101876
McCall et al (1994) Characterization of U-92016A as a selective, orally active, high intrinsic activity 5-hydroxytryptamine1A agonist. J.Pharmacol.Exp.Ther. 271 875 PMID: 7965808
View Related Products by Product Action
Keywords: U 92016A, supplier, Selective, 5-HT1A, agonists, Serotonin, Receptors, U92016A, 5-HT1A, Receptors, 5-HT1A, Receptors, Tocris Bioscience
Citations for U 92016A
Citations are publications that use Tocris products.
Currently there are no citations for U 92016A.
U 92016A Reviews
Average Rating:(Based on 0 Reviews)
Literature in this Area
5-HT Receptors Scientific Review
Written by Nicholas M. Barnes and John F. Neumaier, this review summarizes the various serotonin receptor subtypes and their importance in mediating the role of serotonin in numerous physiological and pharmacological processes. Compounds available from Tocris are listed.
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.